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Abstract: Methamphetamine (METH) is a highly addictive drug, and addiction to METH has increased to epidemic  
proportions worldwide. Chronic use of METH causes psychiatric symptoms, such as hallucinations and delusions, and 
long-term cognitive deficits, which are indistinguishable from paranoid schizophrenia. The GABA receptor system is 
known to play a significant role in modulating the dopaminergic neuronal system, which is related to behavioral changes 
induced by drug abuse. However, few studies have investigated the effects of GABA receptor agonists on cognitive  
deficits induced by METH. In the present review, we show that baclofen, a GABA receptor agonist, is effective in treating 
METH-induced impairment of object recognition memory and prepulse inhibition (PPI) of the startle reflex, a measure of 
sensorimotor gating in mice. Acute and repeated treatment with METH induced a significant impairment of PPI. Further-
more, repeated but not acute treatment of METH resulted in a long-lasting deficit of object recognition memory. Baclofen, 
a GABAB receptor agonist, dose-dependently ameliorated the METH-induced PPI deficits and object recognition memory 
impairment in mice. On the other hand, THIP, a GABAA receptor agonist, had no effect on METH-induced cognitive def-
icits. These results suggest that GABAB receptors may constitute a putative new target in treating cognitive deficits in 
chronic METH users. 
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METHAMPHETAMINE-INDUCED  COGNITIVE 
IMPAIRMENT 
  Methamphetamine (METH) increases the amount of do-
pamine released in synapses by reversing the function of the 
dopamine transporter, which is associated with the rewarding 
effects of the drug [1-4]. Chronic use of METH leads to ad-
diction (dependence) and long-lasting impairment of brain 
function with hallucinations and delusions, which are indis-
tinguishable  from  paranoid  schizophrenia  [5,  6].  Further-
more, chronic METH users show significantly poorer per-
formances on measures of attention/psychomotor speed, ver-
bal learning and  memory, and executive  function, demon-
strating that METH dependence is associated with impair-
ments across a range of neurocognitive domains [7]. 
  Numerous  studies  indicate  that  METH  disrupts  neuro-
transmitter function and in particular the dopaminergic sys-
tem,  although  changes  in  serotonergic,  noradrenergic,  and 
glutamatergic  functions  are  also  observed  [5,  8,  9].  It  has 
been argued that these neuropathological changes underpin 
the  neurocognitive  deficits  associated  with  METH  use  in 
humans [5]. Consistent with this possibility, in a recent me-
ta-analysis of the neurocognitive effects of METH, Scott et 
al. [10] reported significant impairment in several cognitive 
domains that are considered to affect the integrity of these 
neural  substrates,  including  retrospective  memory,  
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information processing speed, and executive operations such 
as inhibitory control. 
  In  order  to  understand  the  etiology  of  METH-induced 
cognitive impairment in chronic METH users, it is necessary 
to establish animal models. Therefore, we investigated the 
effect of METH on learning and memory as well as sensori-
motor  gating  in  rodents.  We  demonstrated  that  repeated 
METH treatment of  mice  followed by  withdrawal impairs 
long-term recognition memory, without affecting learning or 
short-term memory, and that METH-induced cognitive im-
pairment is reversed by an atypical antipsychotic, clozapine, 
but not by haloperidol [11]. Moreover, we have demonstrat-
ed that repeated METH treatment in rats impairs  working 
memory in a delayed spatial win-shift task using a radial arm 
maze and that clozapine, but not haloperidol, is effective in 
improving the METH-induced working memory deficit [12]. 
Because clinical evidence has shown that clozapine is supe-
rior to typical therapeutics such as haloperidol in improving 
cognitive  deficits  in  schizophrenic  patients  [13,  14],  the 
METH-induced  cognitive  impairment  in  rodents  may  be 
useful as an animal model for cognitive deficits in METH 
abusers as well as schizophrenic patients, in which cognitive 
deficits are regarded as a core feature. 
  Our  recent  studies  indicated  that  activation  of  the 
ERK1/2  signaling  pathway,  which  is  associated  with  the 
dopamine D1 receptor [15, 16], plays an important role in 
memory function under physiological and pathological con-
ditions [11, 17-19]. We have also proposed that impairment 
of the dopamine D1 receptor-ERK1/2 signaling pathway in 
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deficits of recognition  memory [11, 20], and that ERK1/2 
activation is related to the performance in working memory 
[19]. On the basis of our findings, Ito et al. [17] and Mizogu-
chi et al. [21] showed that ZSET1446, a novel azaindolizine 
derivative, or minocycline ameliorated METH-induced cog-
nitive impairment through, at least in part, activation of the 
ERK1/2 pathway in the PFC linked to dopamine D1 recep-
tors. 
GABA RECEPTOR  
  The GABA receptor system is known to play a signifi-
cant role in modulating the dopamine system [22]. Baclofen, 
a GABAB receptor agonist, is known to stabilize the firing 
pattern of dopamine neurons [23]. Baclofen has been shown 
to attenuate amphetamine-induced increase in dopamine le-
vels in the nucleus accumbens [24], and GABAA receptors 
on dopamine neurons in the ventral tegmental area play a 
significant role in attenuating the effects of drug abuse in a 
similar manner to that of GABAB receptors [25]. Therefore, 
several studies have demonstrated that GABA receptor agon-
ists can inhibit the effects of drug abuse. For example, pre-
vious studies showed that baclofen reduced the reinforcing 
effects of many substances of abuse, such as cocaine, nico-
tine,  heroin,  and  alcohol  [26],  possibly  through  GABAB-
mediated modulation of mesolimbic dopamine transmission 
[27]. It was demonstrated that chronic coadministration of 
baclofen and amphetamine blocked the development of sen-
sitization to the locomotor stimulation effect of amphetamine 
[28], and acute treatment with baclofen inhibited the expres-
sion of amphetamine-induced locomotor sensitization [29]. 
Moreover, a recent study showed that acute treatment with 
baclofen  ameliorated  ethanol-induced  memory  deficit  in 
mice [30]. 
  Clinical studies have shown significant haplotype associ-
ations between different genes and METH use or the devel-
opment of METH-induced psychosis. In particular, several 
case-control association studies suggest that the human GA-
BAA receptor γ2 subunit gene is marginally associated with 
METH  use  disorder  and  may  be  one  of  the  susceptibility 
genes  of  METH  use  disorder  [31,  32].  Moreover,  several 
clinical studies have demonstrated that GABA agonists in-
cluding topiramate, baclofen and GABA transaminase inhi-
bitor show promise in reducing the METH use/craving [33]. 
Thus, in many studies, the effects of GABA receptor agon-
ists on hyperdopaminergic conditions induced by psychosti-
mulant  drugs  have  been  examined;  however,  few  studies 
have involved investigation of the effects of GABA receptor 
agonists on cognitive deficits induced by drugs abuse. In the 
following sections, we discuss the effects of GABA receptor 
agonists on METH-induced cognitive impairment. 
EFFECTS  OF  GABA  RECEPTOR  AGONISTS  ON 
METH-INDUCED IMPAIRMENT OF RECOGNITION 
MEMORY 
  As described above, repeated treatment with METH (1 
mg/kg, s.c.) for 7 days impairs object recognition memory in 
mice  in  a  novel  objective  recognition  test,  which  is  asso-
ciated with dysfunction of the dopamine D1 receptor-ERK1/2 
pathway  in  the  prefrontal  cortex  [11].  To  develop  novel 
pharmacotherapy for cognitive deficits in METH abusers, we 
examined the effects of GABAA and GABAB receptor agon-
ists in this animal model. 
  We found that acute treatment with baclofen (1-2 mg/kg) 
improved METH-induced cognitive deficit without affecting 
motor function. In contrast, gaboxadol (1-3 mg/kg), a GA-
BAA receptor agonist, had no effect on METH-induced cog-
nitive deficits. These results  suggest that GABAB receptor 
agonists may be useful for the treatment of cognitive deficit 
in METH abusers (Table 1) [34]. Although further studies 
are  necessary  to  clarify  the  molecular  mechanisms  of  the 
action of baclofen, its ameliorating effect on METH-induced 
cognitive deficit may be, at least in part, due to the inhibitory 
effect on METH-evoked hyperphosphorylation of ERK1/2 in 
the PFC. Alternatively, a previous study demonstrated that 
activation of GABAB receptors led to an increase in ERK1/2 
phosphorylation in the CA1 area of mouse hippocampal slic-
es and promoted CREB2-mediated transcription through an 
ERK-dependent mechanism, suggesting that GABAB recep-
tors may play a crucial role in regulating synaptic facilitation 
and memory through regulating protein synthesis and gene 
expression [35]. 
Table 1.  Effects of GABA Receptor Agonist on Methamphe-
tamine-Induced Congnitive Dysfunction in Mice  
  Methamphetamine-Induced Congnitive Impairment 
  Recongnition Memory  Sensorimotor Gating* 
Baclofen 
Gaboxadol  N.D. 
: improvement;  :no effect;  N.D.: not detected. 
*Sensorimotor gating was assessed by the PPI of the acoustic startle reflex. 
EFFECTS  OF  GABA  RECEPTOR  AGONISTS  ON 
METH-INDUCED  DISRUPTION  OF  PREPULSE  
INHIBITION 
  Prepulse inhibition (PPI) of the startle reflex is viewed as 
a measure of a process called ‘sensorimotor gating’. Deficits 
in PPI are observed in patients suffering from certain psy-
chiatric disorders such as schizophrenia [36, 37]. We have 
previously  demonstrated  that  GABAergic  neurons  in  the 
lateral globus pallidus (LGP), which project directly towards 
the  pedunculopontine  tegmental  neurons  (PPTg),  are  acti-
vated by prepulse stimuli but not by startle pulse stimuli and 
play an important role in PPI [38]. It is suggested that the 
pallidotegmental  GABAergic  neurons  act  as  an  interface 
between the brainstem PPI-mediating and the forebrain PPI-
regulating circuits by using c-Fos, a neural activation mark-
er, immunohistochemistry. Moreover, we demonstrated that 
the disruption of PPI caused by METH was accompanied by 
impairment  of  the  LGP  and  hyperactivation  of  the  caudal 
pontine  reticular  nucleus  (PnC),  which  manifested  as 
changes in c-Fos expression in the LGP and PnC after the 
PPI  test;  therefore,  it  is  reasonable  to  assume  that  METH 
disrupts PPI of the startle reflex in mice by inhibiting the 
activation of pallidotegmental GABAergic neurons evoked 
by a prepulse stimulus [39].  Pharmacologic Treatment with GABAB Receptor  Current Neuropharmacology, 2011, Vol. 9, No. 1    111 
  Baclofen (1-5 mg/kg) dose-dependently ameliorated PPI 
impairment  induced  by  acute  treatment  with  METH  (3 
mg/kg) (Table 1), which was associated with the reversal of 
METH-induced  decrease  in  c-Fos  expression  in  LGP,  and 
METH-induced increase in c-Fos expression in PnC. Consis-
tent with our findings, it was reported that baclofen reversed 
the reduction in PPI induced by  MK-801, but  not that by 
apomorphine  (a  direct  dopamine  receptor  agonist),  in  rats 
[40], and that baclofen and clozapine, but not haloperidol, 
improved spontaneous PPI deficit in mice [41]. 
CONCLUSION 
  In conclusion, baclofen acutely ameliorated the cognitive 
deficits in repeated METH-treated mice, an animal model for 
cognitive deficits in METH abuse and schizophrenia. GA-
BAB receptors may constitute a putative new drug target for 
treating cognitive deficits in these patients. Further studies 
are  necessary  to  clarify  the  molecular  mechanisms  of  the 
action of baclofen. 
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